Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1964 3
1965 1
1966 3
1967 5
1968 6
1969 4
1970 8
1971 3
1972 3
1973 1
1975 3
1976 1
1978 5
1979 3
1980 2
1981 2
1982 6
1983 6
1984 3
1985 2
1986 3
1987 3
1988 1
1989 4
1990 3
1991 2
1992 5
1993 5
1994 5
1995 2
1996 4
1997 5
1998 6
2000 3
2001 4
2002 2
2003 1
2004 3
2005 4
2006 11
2007 15
2008 20
2009 16
2010 10
2011 8
2012 9
2013 5
2014 18
2015 14
2016 21
2017 28
2018 18
2019 29
2020 37
2021 35
2022 56
2023 55
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

503 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Li BT, et al. Among authors: nagasaka m. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18. N Engl J Med. 2022. PMID: 34534430 Free PMC article. Clinical Trial.
Neoadjuvant therapy in non-small cell lung cancer.
Grant C, Hagopian G, Nagasaka M. Grant C, et al. Among authors: nagasaka m. Crit Rev Oncol Hematol. 2023 Oct;190:104080. doi: 10.1016/j.critrevonc.2023.104080. Epub 2023 Aug 1. Crit Rev Oncol Hematol. 2023. PMID: 37532102 Free article. Review.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. Among authors: nagasaka m. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. Bannoura SF, et al. Among authors: nagasaka m. Cancer Metastasis Rev. 2021 Sep;40(3):819-835. doi: 10.1007/s10555-021-09990-2. Epub 2021 Sep 9. Cancer Metastasis Rev. 2021. PMID: 34499267 Free PMC article. Review.
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.
Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G Jr, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Judd J, et al. Among authors: nagasaka m. Mol Cancer Ther. 2021 Dec;20(12):2577-2584. doi: 10.1158/1535-7163.MCT-21-0201. Epub 2021 Sep 13. Mol Cancer Ther. 2021. PMID: 34518295 Free PMC article.
Preface.
Nagasaka M, Chen G. Nagasaka M, et al. Cancer Metastasis Rev. 2022 Jun;41(2):245-246. doi: 10.1007/s10555-022-10044-4. Cancer Metastasis Rev. 2022. PMID: 35725839 No abstract available.
503 results